Global Perspectives on the Contribution of B Cells to Multiple Sclerosis: an In-depth Examination and Evaluation

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Nov 29

PMID 39611149

Authors

Xinzhan Jiang

Hongyu Zhang

Yongtao Liu

Bo Sun

Guannan Mu

Affiliations

Soon will be listed here.

Abstract

Background: Multiple sclerosis (MS) is a chronic, progressive autoimmune disease, with increasing attention on the role of B cells in its pathogenesis. Despite this growing interest, a comprehensive analysis of research trends and emerging foci on B cells in MS is currently lacking. In this research, we utilize a bibliometric approach to visualize and analyze research trends and focal points in this field, offering a valuable reference for future mechanistic studies in MS.

Methods: We retrieved bibliometric data from the Web of Science Core Collection (WOSCC) for articles published between 2014 and 2023. VOSviewer 1.6.18 and CiteSpace 5.7R3 were used for co-authorship, co-occurrence, and citation analyses to identify key researchers, institutions, countries, and emerging themes in B cell research related to MS.

Results: The analysis examined 5,578 articles published in 1,041 journals by 5,337 institutions globally. The United States leads in publication output, with Amit Bar-Or identified as the most influential author, and as the top journal in the field. Research has increasingly focused on the complex role of B cells in MS, particularly their involvement in the central nervous system (CNS) and mechanisms of anti-B cell therapy. Recent trends point to a growing focus on meningeal inflammation, kinase inhibitors, and Epstein-Barr virus, signaling a shift in research priorities.

Conclusion: This bibliometric analysis highlights pivotal research trends, key contributors, and emerging areas of interest in B cell research in MS from 2013 to 2024. The findings underscore the growing recognition of the multifaceted role of B cells in MS pathogenesis, particularly their involvement in the CNS compartment and the potential of targeted therapies. The study identifies meningeal inflammation, Epstein-Barr virus infection, and kinase inhibitors as promising avenues for future research. The analyses driving the in-depth exploration of B cell mechanisms in MS and the development of novel diagnostic and therapeutic strategies provide researchers in the MS field with a comprehensive and objective perspective, serving as a valuable reference for accelerating the translation of basic research findings into clinical applications.

References

Padubidri J, Shetty B . Impact factor impacting our scientific research - Probable solutions. Biomed J. 2016; 39(3):226. PMC: 6140299. DOI: 10.1016/j.bj.2016.06.005. View

Chunder R, Schropp V, Marzin M, Amor S, Kuerten S . A Dual Role of Osteopontin in Modifying B Cell Responses. Biomedicines. 2023; 11(7). PMC: 10377065. DOI: 10.3390/biomedicines11071969. View

Yang K, Hu Y, Qi H . Digital Health Literacy: Bibliometric Analysis. J Med Internet Res. 2022; 24(7):e35816. PMC: 9301558. DOI: 10.2196/35816. View

Chen Y, Yin M, Fan L, Jiang X, Xu H, Zhang T . Bibliometric analysis of traditional Chinese medicine research on heart failure in the 21st century based on the WOS database. Heliyon. 2023; 9(1):e12770. PMC: 9860440. DOI: 10.1016/j.heliyon.2022.e12770. View

Varghese J, Kaskow B, von Glehn F, Case J, Li Z, Jule A . Human regulatory memory B cells defined by expression of TIM-1 and TIGIT are dysfunctional in multiple sclerosis. Front Immunol. 2024; 15:1360219. PMC: 11091236. DOI: 10.3389/fimmu.2024.1360219. View

Chitnis T, Weiner H . Targeting Epstein-Barr virus to treat MS. Med. 2022; 3(3):159-161. DOI: 10.1016/j.medj.2022.02.005. View

Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil S . Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1. Neurol Neuroimmunol Neuroinflamm. 2021; 8(1). PMC: 8063619. DOI: 10.1212/NXI.0000000000000918. View

Lv Z, Hou J, Wang Y, Wang X, Wang Y, Wang K . Knowledge-map analysis of bladder cancer immunotherapy. Hum Vaccin Immunother. 2023; 19(3):2267301. PMC: 10760393. DOI: 10.1080/21645515.2023.2267301. View

Cencioni M, Mattoscio M, Magliozzi R, Bar-Or A, Muraro P . B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat Rev Neurol. 2021; 17(7):399-414. DOI: 10.1038/s41582-021-00498-5. View

10.

Zhou Y, Zhang Y, Han J, Yang M, Zhu J, Jin T . Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases. J Transl Med. 2020; 18(1):131. PMC: 7079408. DOI: 10.1186/s12967-020-02289-w. View

11.

Simkins T, Duncan G, Bourdette D . Chronic Demyelination and Axonal Degeneration in Multiple Sclerosis: Pathogenesis and Therapeutic Implications. Curr Neurol Neurosci Rep. 2021; 21(6):26. DOI: 10.1007/s11910-021-01110-5. View

12.

Basak J, Majsterek I . miRNA-Dependent CD4 T Cell Differentiation in the Pathogenesis of Multiple Sclerosis. Mult Scler Int. 2021; 2021:8825588. PMC: 7810561. DOI: 10.1155/2021/8825588. View

13.

Guerrier T, Labalette M, Launay D, Lee-Chang C, Outteryck O, Lefevre G . Proinflammatory B-cell profile in the early phases of MS predicts an active disease. Neurol Neuroimmunol Neuroinflamm. 2018; 5(2):e431. PMC: 5745361. DOI: 10.1212/NXI.0000000000000431. View

14.

Soldan S, Su C, Monaco M, Yoon L, Kannan T, Zankharia U . Multiple sclerosis patient-derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease. Nat Microbiol. 2024; 9(6):1540-1554. PMC: 11900839. DOI: 10.1038/s41564-024-01699-6. View

15.

Bar-Or A, Calabresi P, Arnold D, Arnlod D, Markowitz C, Shafer S . Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008; 63(3):395-400. DOI: 10.1002/ana.21363. View

16.

Steinmaurer A, Riedl C, Konig T, Testa G, Kock U, Bauer J . The relation between BTK expression and iron accumulation of myeloid cells in multiple sclerosis. Brain Pathol. 2024; 34(5):e13240. PMC: 11328345. DOI: 10.1111/bpa.13240. View

17.

Zhang H, Yu H, Zhao G, Jiang X, Gao G, Wei B . Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis. Front Endocrinol (Lausanne). 2023; 14:1273634. PMC: 10585102. DOI: 10.3389/fendo.2023.1273634. View

18.

Vaishya R, Gupta B, Misra A, Mamdapurj G, Vaish A . Global research in sarcopenia: High-cited papers, research institutions, funding agencies and collaborations, 1993-2022. Diabetes Metab Syndr. 2022; 16(11):102654. DOI: 10.1016/j.dsx.2022.102654. View

19.

Storch M, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H . Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol. 1998; 43(4):465-71. DOI: 10.1002/ana.410430409. View

20.

Dent E, Hanlon P, Sim M, Jylhava J, Liu Z, Vetrano D . Recent developments in frailty identification, management, risk factors and prevention: A narrative review of leading journals in geriatrics and gerontology. Ageing Res Rev. 2023; 91:102082. DOI: 10.1016/j.arr.2023.102082. View